Skip to main content


Figure 3 | Intensive Care Medicine Experimental

Figure 3

From: Raxibacumab augments hemodynamic support and improves outcomes during shock with B. anthracis edema toxin alone or together with lethal toxin in canines

Figure 3

Serial mean changes in fluids and hemodynamics for HS. vs. raxibacumab animals in study 1. This figure compares the serial mean (±SEM) changes from baseline in fluid in (A), fluid out (B), net fluid (C), pulmonary capillary wedge pressure (PCWP) (D), norepinephrine use (NE) (E), mean arterial blood pressure (MAP) (F), shock index score (G), heart rate (HR) (H), left ventricular ejection fraction (LVEF) (I), central venous pressure (CVP) (J), cardiac index (CI) (K), and systemic vascular resistance (SVR) (L) for animals receiving hemodynamic support alone (HS, fluids and norepinephrine titrated to pulmonary artery wedge pressure and mean arterial blood pressure, respectively) versus HS combined with raxibacumab administered at the start of (HS + mAbT0) or 6 h (HS + mAbT6) or 12 h (HS + mAbT12) after the start of edema toxin challenge in Study 1. Units of measure are shown in each panel (except for shock index score). *p ≤ 0.05, **p < 0.0001.

Back to article page